Chronic graft-versus-host disease (cGVHD) is a major immunological complication of allogeneic hematopoietic cell transplantation. Chronic GVHD involves multiple organs, reduces quality of life and often requires prolonged therapy with glucocorticoids, causing severe side effects. After four decades of testing multiple therapeutic approaches, the drugs ibrutinib, belumosudil and ruxolitinib were FDA-approved for cGVHD in the last four years. Here we put a spotlight on their mechanisms of action, the studies that led to approval, and their future role in cGVHD.